Rhythm(US:RYTM)2026-01-09 14:06Financial Performance - Rhythm Pharmaceuticals reported preliminary unaudited net revenues of approximately $57 million for Q4 2025, an 11% increase sequentially from Q3 2025[7]. - Full-year 2025 net product revenues are expected to be around $194 million, a 50% increase compared to $130 million in 2024[7]. - U.S. sales of IMCIVREE accounted for approximately 68% of Q4 2025 net product revenues and about 69% of full-year 2025 revenues[7]. - The financial results presented are preliminary and subject to change pending the completion of financial closing and audit procedures[13]. Clinical Trials and Research - The company plans to complete enrollment in the Phase 3 trial substudy for congenital hypothalamic obesity in the first half of 2026[8]. - Topline data from the Phase 3 EMANATE trial for genetically caused MC4R pathway diseases is expected to be announced in Q1 2026[9]. - Positive preliminary data for the exploratory Phase 2 trial of setmelanotide in Prader-Willi Syndrome showed BMI and hyperphagia reductions at months 3 and 6[10]. - A pivotal Phase 3 trial for bivamelagon in acquired hypothalamic obesity is planned for 2026, pending regulatory feedback[11]. - Enrollment in the Phase 1 trial for RM-718 is expected to be completed in Q1 2026[12]. Product Launch and Approvals - The company anticipates launching IMCIVREE in the U.S. for acquired hypothalamic obesity pending FDA approval, with a PDUFA goal date of March 20, 2026[14].